Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Melior Discovery has signed an agreement with AstraZeneca under which Melior's in-vivo theraTrace indications discovery platform will be used to evaluate the therapeutic activity of selected AstraZeneca compounds.
Subscribe to our email newsletter
Melior is using theraTRACE to both build an internal pipeline of development candidates as well as sharing this capability with pharmaceutical and biotechnology company partners.
Andrew Reaume, president and CEO of Melior, said: “Our agreement represents a significant opportunity for Melior to deliver value to AstraZeneca through the application of our unique and innovative in vivo testing platform. We look forward to a productive collaboration.”